GR3021512T3 - Pyridazinediones and their use in the treatment of neurological disorders - Google Patents

Pyridazinediones and their use in the treatment of neurological disorders

Info

Publication number
GR3021512T3
GR3021512T3 GR960402628T GR960402628T GR3021512T3 GR 3021512 T3 GR3021512 T3 GR 3021512T3 GR 960402628 T GR960402628 T GR 960402628T GR 960402628 T GR960402628 T GR 960402628T GR 3021512 T3 GR3021512 T3 GR 3021512T3
Authority
GR
Greece
Prior art keywords
alkyl
opt
substd
phenyl
ring
Prior art date
Application number
GR960402628T
Other languages
English (en)
Inventor
Thomas Michael Bare
Richard Bruce Sparks
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919109973A external-priority patent/GB9109973D0/en
Priority claimed from GB929202991A external-priority patent/GB9202991D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of GR3021512T3 publication Critical patent/GR3021512T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
GR960402628T 1991-05-09 1996-10-31 Pyridazinediones and their use in the treatment of neurological disorders GR3021512T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919109973A GB9109973D0 (en) 1991-05-09 1991-05-09 Therapeutic compositions
GB929202991A GB9202991D0 (en) 1992-02-13 1992-02-13 Compounds

Publications (1)

Publication Number Publication Date
GR3021512T3 true GR3021512T3 (en) 1997-01-31

Family

ID=26298868

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960402628T GR3021512T3 (en) 1991-05-09 1996-10-31 Pyridazinediones and their use in the treatment of neurological disorders

Country Status (21)

Country Link
US (4) US5604227A (el)
EP (1) EP0516297B1 (el)
JP (1) JP3279633B2 (el)
KR (1) KR100231095B1 (el)
AT (1) ATE144707T1 (el)
AU (1) AU642086B2 (el)
CA (1) CA2067537A1 (el)
CZ (1) CZ286814B6 (el)
DE (1) DE69214881T2 (el)
DK (1) DK0516297T3 (el)
ES (1) ES2093782T3 (el)
FI (1) FI102754B (el)
GB (1) GB9208511D0 (el)
GR (1) GR3021512T3 (el)
HU (2) HUT61302A (el)
IE (1) IE921294A1 (el)
IL (1) IL101711A0 (el)
MY (1) MY108482A (el)
NO (1) NO180619C (el)
NZ (1) NZ242540A (el)
SK (1) SK280336B6 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
US5834479A (en) * 1993-03-05 1998-11-10 Mayer; David J. Method and composition for alleviating pain
CA2115792C (en) 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
GB9321854D0 (en) * 1993-10-22 1993-12-15 Zeneca Ltd Pyridazino quinoline compounds
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US5776935A (en) * 1996-07-25 1998-07-07 Merz & Co. Gmbh & Co. Pyrido-phtalazin diones and their use against neurological disorders associated with excitotoxicity and malfunctioning of glutamatergic neurotransmission
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
CZ20013469A3 (cs) * 1999-03-31 2002-04-17 Basf Aktiengesellschaft Diamidy pyridin-2,3-dikarboxylových kyselin
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
KR100965861B1 (ko) 2002-10-24 2010-06-24 삼성전자주식회사 이동통신 시스템에서 복합 재전송 제어 장치
GB0525068D0 (en) * 2005-12-08 2006-01-18 Novartis Ag Organic compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds

Also Published As

Publication number Publication date
DE69214881D1 (de) 1996-12-05
HU9201486D0 (en) 1992-07-28
MY108482A (en) 1996-09-30
FI922099A0 (fi) 1992-05-08
KR920021147A (ko) 1992-12-18
NO180619C (no) 1997-05-21
DE69214881T2 (de) 1997-03-13
EP0516297B1 (en) 1996-10-30
SK280336B6 (sk) 1999-12-10
HUT61302A (en) 1992-12-28
NO180619B (no) 1997-02-10
JPH05140162A (ja) 1993-06-08
AU1521392A (en) 1992-11-12
CS139692A3 (en) 1992-11-18
EP0516297A1 (en) 1992-12-02
GB9208511D0 (en) 1992-06-03
ES2093782T3 (es) 1997-01-01
JP3279633B2 (ja) 2002-04-30
NZ242540A (en) 1994-10-26
IL101711A0 (en) 1992-12-30
NO921841D0 (no) 1992-05-08
KR100231095B1 (ko) 1999-11-15
FI102754B1 (fi) 1999-02-15
CZ286814B6 (cs) 2000-07-12
US5733910A (en) 1998-03-31
NO921841L (no) 1992-11-10
CA2067537A1 (en) 1992-11-10
AU642086B2 (en) 1993-10-07
HU211149A9 (en) 1995-10-30
FI102754B (fi) 1999-02-15
IE921294A1 (en) 1992-11-18
US5599814A (en) 1997-02-04
DK0516297T3 (da) 1997-04-07
FI922099A7 (fi) 1992-11-10
US5604227A (en) 1997-02-18
US5739133A (en) 1998-04-14
ATE144707T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
GB9208511D0 (en) Compounds
PL290758A1 (en) Method of obtaining novel heterocyclene compounds
IL150359A0 (en) Use of chemotherapeutic agents
AU5946986A (en) Herbicidal 5-imidazole carboxylic acid derivatives
GR1000462B (el) Διαδικασια για την παρασκευη των παραγωγων του cephem και των ενδιαμεσων αυτου.
AU8902591A (en) Substituted imidazobenzazepines and imidazopyridoazepines
ATE137116T1 (de) Behandlung von entzündlichen erkrankungen mit 15- ketoprostaglandinen
JPS57176988A (en) Penam-3-carboxylic acid derivative and its preparation
ES476682A1 (es) Un procedimiento para la preparacion de nuevos dericados de 1-aza-biciclo (2,2,2)octano, utiles como psicotrupos.
JPS5618967A (en) Azolyllalkenol* its manufacture and its use as bactericide
DE3272158D1 (en) Use of basically substituted phenylacetonitriles in the prophylactic treatment of illnesses
FR2267102A1 (en) 2,6-Di(branched alkylamino)pyridines - for treatment of fatty degeneration and diabetes
EP0469782A3 (en) Treatment of cataract with prostacyclin compounds
ES8106147A1 (es) Procedimiento para preparar un 1,2,4-triazol-3-tiol
ES8302719A1 (es) Un procedimiento para preparar compuestos de cefem
ES410992A1 (es) Procedimiento para la fabricacion de materias sinteticas que llevan grupos de uretano.
EP0148007A3 (en) Cephalosporin compounds and medicaments and their production
ATA502477A (de) Verfahren zur herstellung von neuen n-acylamino-alfa-arylacetamidocephalosporinderivaten und deren salzen
HK37688A (en) Novel amidines,processes for their manufacture,pharmaceutical preparations containing them,and their use
NL7510483A (en) Alpha-ureido-thienylacetamido-cephalosporanic acids - with broad-spectrum antibacterial activity for oral or parenteral admin., for disinfection and as additives for animal feeds
JPS5337689A (en) Compounds having antibacterial activity
SU1088319A1 (ru) 2-Ацетилгидразино-4-(3,4-диоксифенил)-тиазол, проявляющий антимикробную активность в отношении кишечной палочки и золотистого стафилококка